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Abstract
Ovarian cancer is the most lethal of all of the gynecological cancers and can arise from any cell type
of the ovary, including germ cells, granulosa or stromal cells. However, the majority of ovarian
cancers arise from the surface epithelium, a single layer of cells that covers the surface of the ovary.
The lack of a reliable and specific method for the early detection of epithelial ovarian cancer results
in diagnosis occurring most commonly at late clinical stages, when treatment is less effective. In
part, the deficiency in diagnostic tools is due to the lack of markers for the detection of
preneoplastic or early neoplastic changes in the epithelial cells, which reflects our rather poor
understanding of this process. Animal models which accurately represent the cellular and molecular
changes associated with the initiation and progression of human ovarian cancer have significant
potential to facilitate the development of better methods for the early detection and treatment of
ovarian cancer. This review describes some of the experimental animal models of ovarian
tumorigenesis that have been reported, including those involving specific reproductive factors and
environmental toxins. Consideration has also been given to the recent progress in modeling
ovarian cancer using genetically engineered mice.
Introduction
Despite improved knowledge of the etiology of ovarian
cancer, aggressive cytoreductive surgery, and modern
combination chemotherapy, there has been little change
in the mortality statistics over the last 30 years, and
approximately 60% of the women who develop ovarian
cancer will die from their disease. Lack of an adequate
screening test for early disease detection and the rapid
progression to chemoresistance have prevented apprecia-
ble improvement in the five year survival rate of patients
with ovarian cancer.
Experimental models for human diseases are of crucial
importance not only to understand the biological and
genetic factors that influence the phenotypic characteris-
tics of the disease but to utilize as a basis for developing
rational intervention strategies. Ovarian cancer cell lines
derived from ascites or primary ovarian tumors have been
used extensively and can be very effective for studying the
processes controlling growth regulation and chemosensi-
tivity. Our limited knowledge of the initiating events of
ovarian cancer has restricted the development of models
in which the early pathogenic events for ovarian cancer
can be studied. However, there are a few animal models
that develop ovarian tumors spontaneously, and others
where the manipulation of various reproductive factors or
exposure to environmental toxins have been shown to
promote ovarian tumorigenesis. Finally, the recent
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identification of promoters that can drive gene expression
in the ovarian surface epithelium is providing new oppor-
tunities for the generation of genetically engineered
mouse models of ovarian cancer. Here we describe some
of the models that have been developed to investigate
ovarian cell transformation.
Spontaneous and Non-epithelial Ovarian 
Tumorigenesis
There are few animal models that develop ovarian tumors
spontaneously. Hens maintained under intensive egg-lay-
ing conditions develop ovarian adenocarcinomas; how-
ever such tumors are uncommon in hens less than 2 years
of age [1]. Ovarian tumors will also arise spontaneously
with age in some strains of mice [2], and in Wistar and
Sprague-Dawley rats [3,4]. These tumors show a wide vari-
ety of histologic sub-types, including tubular adenoma,
adenocarcinoma, papillary cystadenoma, mesothelioma,
granulosa cell tumor, and polycystic sex cord/stromal
tumor. However, the low incidence and/or the length of
time required for the appearance of tumors in all of these
models render them poorly feasible for experimental
studies of ovarian carcinogenesis.
Some strains of mice, including C3HeB/Fe and C3HeB/
De, show a high incidence of spontaneously occurring
granulosa cell tumors and tubular adenomas [5]. Strain
HAN:NMRI develop spontaneous Sertoli cell-like tumors
and (DBA × Ce)F1 hybrids have a high incidence granu-
losa cell tumors [5]. Granulosa cell tumors also appear
spontaneously at 4–6 weeks of age in SWR/J and in SWR/
Bm inbred strain mice, with a maximum incidence
reached by 10 weeks [6]. In some SWXJ strains, granulosa
cell tumors occur spontaneously, and in others granulosa
tumors can only be induced by treatment with dehydroe-
piandrosterone [7].
Spontaneous germ cell tumors are less common, but have
been reported in LT/Sv and related strains of mice. These
mice have a high frequency of spontaneous ovarian ter-
atomas arising from follicular oocytes that undergo par-
thenogenetic activation. In some strains, this defect
appears to be associated with an arrest of the oocytes at
metaphase of meiosis I [8]. Teratomas arising from par-
thenogenetic activation of oocytes also occur in c-mos-
deficient oocytes, which fail to maintain meiotic arrest
after oocyte maturation [9,10].
Mice generated to be deficient in the tumor suppressor
gene Lats1 exhibit a lack of mammary gland development,
infertility and growth retardation. Accompanying these
defects are hyperplastic changes in the pituitary and
decreased serum hormone levels. The reproductive hor-
mone defects of Lats1-/- mice are reminiscent of isolated
LH-hypogonadotropic hypogonadism and corpus luteum
insufficiency in humans. Lats1-/- mice develop soft-tissue
sarcomas and ovarian stromal cell tumors [11].
The Ovarian Surface Epithelium
Although ovarian cancer in humans can arise from any of
the cell types found in the ovary, almost 90% are derived
from the ovarian surface epithelium (OSE) [12]. The OSE
covers the entire ovarian surface, and varies morphologi-
cally from simple squamous to cuboidal to low pseudos-
tratified columnar [13,14]. Embryologically derived from
the mesodermal epithelium of the gonadal ridges, OSE
cells are continuous with the flattened mesothelium of
the peritoneum [15] and are separated from the underly-
ing stromal compartment of the ovary by a basement
membrane. Immunohistochemical staining has shown
that OSE cells express cytokeratin, desmoplakin, trans-
forming growth factor-α (TGF-α) and receptors for estro-
gen, progesterone and epidermal growth factor (EGF)
[16–20]. Despite their rather unremarkable appearance in
vivo, it is believed that OSE cells actively participate in the
ovulatory process. Studies in rabbits and sheep have
shown that OSE release proteolytic enzymes that degrade
the basement membrane and the underlying apical follic-
ular wall, weakening the ovarian surface to the point of
rupture [21]. The OSE cells directly over the point of rup-
ture undergo apoptotic cell death before ovulation [22]
and the wound created at the ovulatory site surface is
repaired by rapid proliferation of OSE cells from the
perimeter of the ruptured follicle [23]. The biology, endo-
crinology and pathology of the ovarian surface epithelium
have recently been reviewed in detail [24].
Although the ovarian surface is generally smooth in early
reproductive life, with aging the ovary becomes more con-
voluted. Invaginations of the epithelium result in crypts
or gland-like structures that can become pinched off to
form epithelial inclusion cysts within the underlying stro-
mal compartment [25]. This may occur following the pos-
tovulatory proliferation of OSE, follicular attrition, and/
or from inflammation caused by carcinogens or chemical
irritants like talcum powder [26]. The incidence of inclu-
sion cysts increases with advancing age and are common
in postmenopausal women. Although generally benign in
nature, these epithelial rearrangements are widely
thought to be the potential origin of many epithelial can-
cers. The more frequent appearance of epithelial invagina-
tions and inclusion cysts in women with hereditary risk of
ovarian cancer has strengthened this hypothesis [27]. In
addition, some microscopic borderline and malignant
tumors have been observed to arise directly within these
sites, and they are often associated with dysplasia in simi-
lar sites elsewhere in the same or contralateral ovary
[28,29].Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/67
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Xenografts of OSE Cells Transformed in vitro
OSE cells have been implicated as the cell of origin for the
majority of ovarian cancers based primarily on histologi-
cal and immunohistochemical analyses of patient sam-
ples, but several recent experimental models
manipulating these cells in vitro have provided additional
support for this concept. Primary culture of human OSE
was first reported by Auersperg et al. in 1984 [30], and her
group has since developed several in vitro models of ovar-
ian epithelial carcinogenesis. Introduction of Kirsten
murine sarcoma virus into rat OSE cells results in
endometrioid tumors following subcutaneous or intra-
peritoneal injection into immunosuppressed rats [31].
Transfection of SV40 T antigen early genes induces
immortalization of human OSE cells that delays, but does
not prevent, the senescence that normally occurs after a
few passages [32]. Introduction of E-cadherin into these T
antigen-immortalized cells induces epithelial differentia-
tion [33] and the cells formed transplantable, invasive
adenocarcinomas when injected into SCID mice [34]. In
contrast to T antigen-immortalized cells, introduction of
the human papilloma virus E6 and E7 genes into human
OSE cells results in the spontaneous progression from a
benign to invasive phenotype [35].
Unlike human OSE, rat and mouse OSE do not senesce.
Rat OSE cells that have spontaneously immortalized but
are not tumorigenic (eg. ROSE 199 cells; [36]) have been
used in a variety of experiments, including some to char-
acterize the cellular features when SV40 T antigen or H-ras
is introduced into immortalized cells and following the
formation of tumors when these cells are xenografted into
nude mice [37]. Repeated subculture of rat and mouse
OSE cells to maintain continued proliferation results in
spontaneous malignant transformation, as characterized
by loss of contact inhibition, substrate-independent
growth and the ability to form tumors in nude mice
[38,39]. In a variation of the above in vitro transformation
approaches, Orsulic and colleagues used the RCAS retro-
viral vector to introduce oncogenes into OSE cells from
transgenic mice bearing the RCAS receptor TVA and the
cells were evaluated for tumorigenicity by injection into
immune-deficient or syngeneic animals [40]. The investi-
gators found that p53 deficiency in combination with two
oncogenes from among C-MYC,  K-RAS,  or  AKT  were
required to achieve transformation.
While these models allow an evaluation of oncogenes
whose activation may contribute to the development of
epithelial ovarian cancer, this approach does not allow
the investigation of the early events in ovarian tumorigen-
esis inherent in mice when the tumors arise in situ. How-
ever, the establishment of in vitro models of normal and
transformed OSE cells has provided the opportunity to
use molecular approaches such as microarray or suppres-
sion subtractive hybridization to identify differential gene
expression patterns that can distinguish normal OSE and
ovarian cancer cells [41,42]. These data will be useful for
the elucidation of molecular events associated with OSE
cell transformation.
Xenografts of Cancer Cells
Xenograft models, where ovarian cancer cells have been
injected either subcutaneously or into the peritoneal cav-
ity have been used extensively for the testing of novel ther-
apeutics or modified regimens for administration of
standard chemotherapeutic drugs [43–45]. Some mouse
models take advantage of the presence of a bursa, a sac-
like structure that envelops rodent ovaries. For decades,
researchers have used the intra-bursal space for trans-
plants of xenografted ovaries, or to facilitate direct expo-
sure of the ovary to various factors. For the generation of
mouse models of ovarian cancer, the injection of ovarian
cancer cells into the intra-bursal space results in tumor
formation that can perhaps be viewed as more physiolog-
ical (Figure 1), as the cancer cells are placed directly in the
environment where ovarian tumors normally arise [46].
Reproductive Factors and Ovarian 
Tumorigenesis
Unlike most other cancers, the series of events involved in
the initiation, progression and metastasis of ovarian can-
cer is not yet established. It is not clear if malignancies
arise from benign or borderline tumors or if they develop
de novo from the surface epithelium or inclusion cysts, as
there is evidence for both [47]. The incidence of ovarian
cancer climbs dramatically in women around the age at
which they reach menopause. The reason for this is not
clear, but two of the major changes associated with men-
opause form the foundation for hypotheses regarding the
origin of ovarian tumors: 1) the depletion of oocytes or
germ cells, which is the underlying cause of menopause,
and 2) a significant increase in the pituitary's production
of the gonadotropic hormones, follicle-stimulating hor-
mone (FSH) and luteinizing hormone (LH), that arises as
a consequence of the reduced follicular estrogen levels. In
addition to the loss of germ cells and the associated alter-
ations in hormone levels which normally occur at meno-
pause, there are a number of non-menopausal factors that
have been shown to have physiological relevance in epi-
thelial ovarian tumorigenesis, including ovulation. Each
of these will be discussed in the context of the animal
models that have resulted from the experimental manipu-
lations of these factors.
Ovulation
The "incessant ovulation hypothesis" proposes that con-
tinuous ovulation, with its successive rounds of surface
rupture and OSE cell mitosis to repair the wound, renders
the cells susceptible to malignant transformation [48].Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/67
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Anecdotal support for this hypothesis comes from the
observation that intensive egg-laying domestic hens fre-
quently develop peritoneal carcinomata that is presuma-
bly of ovarian origin [1]. Epidemiological studies indicate
that circumstances that decrease the number of ovula-
tions, i.e., pregnancy, oral contraceptive usage, duration
of lactation and early menopause, all substantially reduce
the risk of ovarian cancer [49,50].
Inherent in the incessant ovulation hypothesis for ovarian
cancer risk is the premise that repetitive damage of the
OSE at ovulation and/or the subsequent mitotic repair
following ovulation increases the risk of developing ovar-
ian cancer. Experimental evidence to support the suscepti-
bility of OSE cells to mutagenic events during mitosis is
provided by studies showing that primary cultures of nor-
mal rat and mouse OSE cells which have been repeatedly
subcultured to maintain continued proliferation acquire
features associated with malignant transformation,
including loss of contact inhibition, substrate-independ-
ent growth and the ability to form tumors in nude mice
[38,39].
The risk generated by incessant ovulation may also be
associated with the formation of epithelial cell-lined
inclusion cysts that are frequently found in the ovarian
stroma of perimenopausal women. As noted above, these
inclusion cysts may form as a result of the process of ovu-
lation and the pinching off of deep clefts [47]. In mice, the
lifetime total number of ovulations is associated with a
marked increase in OSE invagination and stratification
[51], although the incidence of inclusion cysts was more
related to age than to number of ovulations. Therefore,
unlike in humans, an association between number of ovu-
lations and ovarian cancer risk has not been demonstrated
in rodents.
Gonadotropins
An alternative, but not mutually exclusive, hypothesis for
the mechanism of ovarian carcinogenesis proposes that
the development of ovarian tumors is related to excessive
gonadotropin production associated with the onset of
menopause or premature ovarian failure [52]. The median
age for epithelial ovarian cancer is 60–65 years, with only
10–15% of the tumors appearing in premenopausal
women [53]. Serum FSH and LH levels reach their peak
during perimenopausal and postmenopausal years and
remain elevated thereafter [54]. High circulating levels of
pituitary gonadotropins may increase the risk of ovarian
cancer by stimulating the growth of ovarian epithelial
Development of ovarian tumors following injection of ES-2 ovarian cancer cells under the bursal membrane of nude mouse  ovaries Figure 1
Development of ovarian tumors following injection of ES-2 ovarian cancer cells under the bursal membrane of nude mouse 
ovaries. Left figure- Proliferating cancer cells invade the normal tissue and increase the ovarian mass to diameters > 10-fold in 
size (indicated by arrows). Right figure- A single follicle containing a growing oocyte, indicated by an arrow, is clearly visible in 
the mass of tumor tissue.Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/67
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cells, since normal human OSE cells and epithelial inclu-
sions have been found to express receptors for FSH [55]
and LH/hCG [56]. Enhanced cell proliferation in response
to FSH and/or LH/hCG has been reported for primary cul-
tures of rabbit [57], mouse [58] and human [56] OSE
cells. Schiffenbauer and colleagues [59] found that
human epithelial ovarian cancers progressed faster in ova-
riectomized mice due to elevated FSH and LH levels,
which promoted increased vascular endothelial growth
factor expression and tumor neovascularization.
The gonadotropin theory of ovarian tumorigenesis sug-
gests that elevated gonadotropin concentrations contrib-
ute to the development of ovarian tumors. This theory is
based on the initial observation of Biskind and Biskind in
1944 [60] who reported that transplantation of ovaries
into the splenic pulp of adult rats led to the development
of ovarian tumors. The tumorigenesis was attributed to
inactivation of estrogen in the liver, and the consequent
elevation of gonadotropin levels due to the lack of steroid
feedback on the pituitary. Several transgenic or knockout
animal models in which gonadotropin levels are elevated
also result in ovarian tumorigenesis. For example, when
inhibin, the ovarian protein that inhibits the production
of FSH, is made deficient in mice, gonadal stromal tumors
arise [61]. Transgenic mice generated to have chronic LH
hypersecretion develop granulosa cell tumors or luteo-
mas, depending on the background strain [62,63]. Mice
with disruption of the FSH receptor are acyclic and sterile,
with very small, underdeveloped ovaries; they exhibit
hypergonadotropic-hypogonadism with high levels of cir-
culating FSH and LH similar to the postmenopausal state
in women. By 12 months, more than 92% of these ani-
mals developed various kinds of ovarian pathology,
including neoplasms of sex cord-stromal type as well as
cysts, suggesting that FSH receptor insensitivity in the face
of prolonged elevated levels of gonadotropins may be
contributing to the development of ovarian granulosa or
stromal tumors [64]. None of the animal models with tar-
geted manipulation of gonadotropin secretion or action
appear to promote ovarian epithelial tumorigenesis.
Steroid hormones
In the developing fetal ovary, marked OSE cell prolifera-
tion occurs at 16 to 20 weeks of gestation, coincident with
the appearance of steroid-producing cells in the ovarian
cortex [65]. Adult human OSE cells express receptors for
estrogen, progesterone and androgens [66,67], and
human OSE cell proliferation can be stimulated by andro-
gens [68]. In contrast, human OSE cells in culture are
reportedly unaffected by estradiol or progesterone [66],
which would suggest that these steroid hormones do not
have a significant role in ovarian tumorigenesis. However,
a recent study has found that menopausal women who
have taken hormone replacement therapy using estrogen
only are at an increased risk of ovarian cancer [69]. In ani-
mals, continuous exposure to estradiol stimulates sheep
OSE cell proliferation [70], while in guinea pigs and rab-
bits, it results in the formation of a papillary ovarian sur-
face resembling human serous neoplasms of low
malignant potential [71,72]. The mechanisms by which
estrogen may contribute to ovarian cancer risk is
unknown, but could be direct action on the OSE cells, or
may be indirect, as estrogen reduces GnRH receptor
expression in both OSE and ovarian cancer cells, thereby
suppressing the growth inhibitory effects of GnRH [73].
Estrogen also modulates levels of hepatocyte growth fac-
tor which stimulates OSE cell growth [74].
A number of studies, largely epidemiological, provide
support for the hypothesis that androgens are involved in
ovarian carcinogenesis. Over 80% of tumors express AR
[75] and an increased risk of ovarian cancer was found in
women with elevated circulating levels of androgens [76].
Testosterone-stimulated growth of OSE cells in guinea
pigs caused the formation of benign cysts, small adeno-
mas in the ovarian parenchyma, and papillomas on the
ovarian surface [77]. Androgens may promote ovarian
tumorigenesis in part by decreasing TGF-β receptor levels,
thereby allowing ovarian cancer cells to escape TGF-β
growth inhibition [78].
Germ cell deficiency/depletion
Aging and hereditary risk are associated with a more fre-
quent incidence of epithelial invaginations and inclusion
cysts, putative preneoplastic precursor lesions, but the
underlying mechanisms for these epithelial-stromal rear-
rangements are unknown. OSE cell hyperplasia with stro-
mal invasion has been reported in a diverse array of
experimental situations, all of them involving loss of germ
cells and consequent failure of follicle development. For
example, mutations at the W (Kit) or Sl (Kitl) loci result in
sterility by preventing the normal proliferation and migra-
tion of germ cells during fetal development [79]. Germ
cell deficiency in vivo, as is found in Wx/Wv mice, results in
bilateral ovarian tubular adenomas in more than 95% of
the animals by 5 months of age [80,81]. The tumors arise
from interstitial cell hyperplasia, with proliferation and
invasion of the ovarian surface epithelium into the stro-
mal compartment of the ovary. Invasive epithelial tubules
are also found in Sl/Slt germ cell deficient mice by 7
months of age [82], and mice heterozygous for the Sld
mutation, which carries a splicing defect, develop papil-
lary structures and epithelial invaginations (Figure 2),
similar to that seen in women [26]. Likewise, female mice
homozygous for the germ cell deficient (gcd) mutation
enter reproductive senescence prematurely due to a dearth
of germ cells. By one year of age, 56% of homozygotes
have developed ovarian tubulostromal adenomas while
wild-type littermates are phenotypically normal [83].Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/67
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Morphology of the ovarian surface epithelium in wild-type (A; 12 months), Sld heterozygous (B, C; 12 months) and homozygous  (D; 6 months) mice Figure 2
Morphology of the ovarian surface epithelium in wild-type (A; 12 months), Sld heterozygous (B, C; 12 months) and homozygous 
(D; 6 months) mice. Ovaries from wild-type mice contain developing follicles and a covering layer of columnar OSE. In 12-
month-old Sld heterozygous mice, there is a depletion of follicles, and the ovarian surface has become very convoluted (B), with 
this papillary surface sometimes leading to deep invaginations, as indicated by the arrow (C). By 6 months of age, the ovaries of 
homozygous Sld mice are completely abnormal, with no recognizable ovarian structures, and are composed primarily of inva-
sive epithelial tubules. (E) Human ovarian papillomatosis, for comparison.
A
D
C
B
C
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Therefore, it appears that oocyte depletion is associated
with formation of epithelial structures that resemble the
preneoplastic lesions in human ovaries.
Experimental ovarian tumorigenesis has been investigated
in inbred and hybrid strains of mice and induced by a
diversity of mechanisms including X-irradiation, oocyto-
toxic xenobiotic chemicals, ovarian grafting to ectopic or
orthotopic sites, neonatal thymectomy, genetic defects
reducing germ cell populations, and aging [reviewed in
[84]]. While germ cell deficiency seems to be a required
element for the development of epithelium-derived ade-
nomas, the mechanisms by which germ cell loss contrib-
utes to tumorigenesis in these models remain unclear.
Ovarian follicles do not develop in the absence of oocytes,
indicating that the oocyte directs the development of fol-
licles. Pathogenetic factors that prematurely destroy or
diminish the numbers of germ cells lead to failure in fol-
licle development and a resulting decrease in sex steroid
hormone secretion (notably estradiol) leading to a com-
pensatory over-production of pituitary gonadotropins,
which places the ovary at an increased risk to develop
tumors. Therefore oocyte depletion, similar to that which
occurs naturally by the time of menopause, may be a con-
tributing factor to the oncogenic behavior of the surface
epithelial cells.
The intense proliferation of OSE and stromal (interstitial)
cells with the development of unique tubular adenomas
in response to sterility seems to require both the lack of
germ cells/follicles and the increased production of gona-
dotropins. Elevated gonadotropins alone resulted in gran-
ulosa cell tumors or luteomas [62,63]. Oocyte destruction
by gamma irradiation in hypogonadal mice deficient in
gonadotropins did not result in the development of tubu-
lar adenomas [85]. Similarly, the experimental suppres-
sion of gonadotropin levels in Wx/Wv mice was sufficient
to prevent the development of ovarian tubular adenomas
from the surface epithelium [86], suggesting that both
oocyte loss/destruction and elevated gonadotropins are
necessary for epithelial tumorigenesis.
Environmental Carcinogens
Although the more established hypotheses that have been
proposed to explain increased risk of developing ovarian
cancer are related to the number of ovulations or to
increased hormone levels, there are additional risk factors
that have been identified, including a number of environ-
mental carcinogens. While these factors have been
reported to have effects on the ovarian surface epithelium,
they are usually also associated with follicular destruction
and/or ovotoxicity, so indirect actions due to altered
gonadotropin levels cannot be eliminated. Use of perineal
talc has been identified as a risk factor, possibly due to its
ability to ascend the genital tract and affect the ovarian
surface [87]. Indeed, direct exposure of rat ovaries to talc
results in focal areas of papillary change in the ovarian
surface epithelium, as well as ovarian cysts [88]. Exposure
of rhesus and cynomolgus monkeys to the environmental
pollutant, hexachlorobenzene results in both reproduc-
tive failure and notable alterations in the size, shape and
degree of stratification of the OSE cell layer [89]. More
recent studies have shown that the insecticide methoxy-
chlor increases both the height of the OSE cell layer and
the percentage of atretic follicles in exposed mice [90]. In
rodent studies, ovarian toxicity and/or carcinogenicity has
been documented for at least eight chemicals that result in
follicular necrosis, tubular hyperplasia, granulosa cell
tumors and benign mixed tumors [91,92]. N-ethyl-N-
nitrosourea administered to rats intraperitoneally or
transplacentally increases the incidence of ovarian tubular
adenomas [93]. The mechanisms by which these environ-
mental carcinogens enhance the risk of ovarian tumors
remain unexplored.
Transgenics and Targeted Approaches to 
Transform the Ovarian Epithelium
The ideal model to investigate the pathogenic events asso-
ciated with early ovarian tumorigenesis would be a mouse
model in which the tumor arises directly from the OSE
cells. This model would differ from current xenograft
models in that transgenic mice with defined genetic
lesions could be studied at various stages as they inevita-
bly develop ovarian cancer in situ. In addition, the devel-
opment of a genetic model would permit the direct testing
of oncogenes and tumor suppressors for their
contribution to the initiation and progression of overt
malignancies in the mouse ovary. Finally, a number of dif-
ferent factors could be altered such as the genetic back-
ground of the mouse strain, the frequency of ovulation
and the levels of various hormones to determine their
impact on the development of tumors in the susceptible
transgenic mouse line.
One approach to alter gene expression directly in the OSE
cells would be to take advantage of the fact that these cells
readily take up and express genes delivered by intra-bursal
injection of adenoviruses [94,95]. This method has the
potential advantage of mimicking somatic mutations that
contribute to early ovarian tumorigenesis. One recent
report used intra-bursal adenovirus delivery and Cre-loxP
mediated gene inactivation to render OSE cells deficient
in two key tumor suppressor genes: p53 and Rb [95]. The
p53 tumor suppressor gene is the most frequently
mutated gene in human neoplasms. Mutations and/or
over-expression of p53 have been described in 26–62% of
ovarian cancers, particularly serous ovarian carcinomas
[reviewed in [96]]. Aberrations in the Rb pathway have
been reported [97]; however, direct evidence for their con-
tribution to ovarian epithelial tumorigenesis is lacking. InReproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/67
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this model, recombinant adenovirus expressing Cre was
injected under the ovarian bursal membrane of double
transgenic mice bearing floxed copies of p53 and Rb. Con-
current inactivation of p53 and Rb was sufficient for
reproducible induction of ovarian epithelial carcinogene-
sis in mice homozygous for the conditional alleles. While
less than 15% of mice with inactivation of either Rb or p53
developed tumors, 33 of 34 mice with deficiencies in both
genes succumbed to their ovarian cancers at a median of
227 days, with 24% having abdominal ascites.
The major impediment to the development of transgenic
models of ovarian cancer is the lack of specific promoters
able to direct gene expression to OSE cells. Previous mod-
els of ovarian cancer have resulted in granulosa cell
tumors using promoters, such as inhibin-alpha subunit
promoter, that are active in this cell type to drive the
expression of the large T antigen of SV40 [98,99]. Recent
studies have identified two other promoters that may
prove to be useful for the generation of transgenic models
of ovarian cancer. The Ovarian Specific Promoter (OSP-1)
was developed from a retrovirus-like element specifically
expressed in the rat ovary. The promoter drives gene
expression specifically in normal and neoplastic ovarian
epithelial cells [100] and expression of lacZ  driven by
OSP-1 in transgenic mice was restricted to the ovary as
determined by X-gal staining of multiple organs [101].
Immunohistochemical detection of β-galactosidase
showed lacZ expression mainly in the granulosa cells and
ovarian surface epithelial cells. However, transgenic mice
in which OSP-1 drives the expression of the early region
of SV40 virus developed tumors in a variety of tissues,
including unilateral granulosa cell tumors in two of three
female founder mice. Thus, although transcription from
the OSP-1 promoter occurs predominantly in the ovary,
this promoter is sufficiently "leaky" in cells in other tis-
sues to permit their tumorigenic conversion by SV40 TAg.
The first transgenic model of epithelial ovarian cancer was
recently reported and used the upstream region of the
Mullerian inhibitory substance type II receptor (MISIIR)
gene to drive tissue-specific expression [102]. MISIIR is a
single transmembrane serine/threonine kinase that shares
homology with the TGFβ-receptor [103,104]. Expression
of MISIIR has been reported to be restricted to mesenchy-
mal cells surrounding the Mullerian duct during embryo-
genesis, tubular and follicular structures of fetal gonads,
Sertoli and Leydig cells of adult testis, and granulosa cells
of adult ovary [103,105,106]. More recently, expression of
MISIIR in established human ovarian cancer cell lines as
well as cell lines derived from the ascites of patients with
ovarian carcinomas has been demonstrated [107]. Trans-
genic mice in which the 5' upstream regulatory sequences
of the mouse MISIIR gene were used to target expression
of the SV40 TAg  specifically to the epithelium of the
female mouse reproductive tract, including the OSE,
developed ovarian carcinomas with metastatic spread to
peritoneal organs by 3 months of age. Female transgenic
mice developed bilateral ovarian tumors in ~50% percent
of cases. Histologically, these tumors were poorly differ-
entiated carcinomas with occasional cysts and papillary
structures present at the surface of the ovary. These tumors
disseminated intraperitoneally, invaded the omentum
and formed ascites in a manner that resembles human
ovarian carcinomas. The demonstration that the MISIIR
promoter can be used successfully to drive gynecological
tissue-specific transgene expression in mice and that this
often results in the formation of ovarian carcinoma offers
very promising opportunities for testing the efficacy of
chemotherapeutic and chemopreventive agents in a herit-
able model of epithelial ovarian cancer.
Conclusions
The two most pressing problems in the management of
ovarian cancer are the lack of adequate diagnostic or
screening strategies, and the recurrence of disease that is
often chemoresistant. In part, the deficiency in diagnostic
tools is due to the lack of markers for the detection of pre-
neoplastic or early neoplastic changes in the OSE cells.
The generation of animal models in which OSE cells
undergo neoplastic transformation in vivo will provide
much-needed opportunities to investigate the cellular and
molecular changes associated with the initiation of OSE
cell transformation, as well as to provide models in which
prevention, diagnostic, screening and therapeutic strate-
gies can be developed.
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